This is the straightforward reply: VIP is not really a normal-objective anti-inflammatory peptide you'll be able to substitute into any protocol expecting wide immune suppression. Its effects are receptor-particular, tissue-dependent, and timing-sensitive in ways in which make protocol layout substantially far more complex than simply just dosing a